189 related articles for article (PubMed ID: 30419852)
1. Epithelial cell adhesion molecule (EpCAM) is involved in prostate cancer chemotherapy/radiotherapy response in vivo.
Ni J; Cozzi P; Beretov J; Duan W; Bucci J; Graham P; Li Y
BMC Cancer; 2018 Nov; 18(1):1092. PubMed ID: 30419852
[TBL] [Abstract][Full Text] [Related]
2. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
[TBL] [Abstract][Full Text] [Related]
3. CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo.
Ni J; Cheung BB; Beretov J; Duan W; Bucci J; Malouf D; Graham P; Li Y
Exp Cell Res; 2020 Mar; 388(2):111850. PubMed ID: 31954695
[TBL] [Abstract][Full Text] [Related]
4. Silencing of EPCAM suppresses hepatic fibrosis and hepatic stellate cell proliferation in mice with alcoholic hepatitis via the PI3K/Akt/mTOR signaling pathway.
Zhang Z; Wen H; Weng J; Feng L; Liu H; Hu X; Zeng F
Cell Cycle; 2019 Sep; 18(18):2239-2254. PubMed ID: 31378124
[TBL] [Abstract][Full Text] [Related]
5. Epithelial cell adhesion molecule overexpression regulates epithelial-mesenchymal transition, stemness and metastasis of nasopharyngeal carcinoma cells via the PTEN/AKT/mTOR pathway.
Wang MH; Sun R; Zhou XM; Zhang MY; Lu JB; Yang Y; Zeng LS; Yang XZ; Shi L; Xiao RW; Wang HY; Mai SJ
Cell Death Dis; 2018 Jan; 9(1):2. PubMed ID: 29305578
[TBL] [Abstract][Full Text] [Related]
6. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.
Ni J; Cozzi PJ; Hao JL; Beretov J; Chang L; Duan W; Shigdar S; Delprado WJ; Graham PH; Bucci J; Kearsley JH; Li Y
Prostate; 2014 May; 74(6):602-17. PubMed ID: 24615685
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of short hairpin RNA targeting integrin-linked kinase in prostate cancer cells.
Yuan Y; Xiao Y; Li Q; Liu Z; Zhang X; Qin C; Xie J; Wang X; Xu T
Mol Med Rep; 2013 Aug; 8(2):419-24. PubMed ID: 23783575
[TBL] [Abstract][Full Text] [Related]
8. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
9. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
Hao J; Madigan MC; Khatri A; Power CA; Hung TT; Beretov J; Chang L; Xiao W; Cozzi PJ; Graham PH; Kearsley JH; Li Y
PLoS One; 2012; 7(8):e40716. PubMed ID: 22870202
[TBL] [Abstract][Full Text] [Related]
11. Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.
Hao J; Graham P; Chang L; Ni J; Wasinger V; Beretov J; Deng J; Duan W; Bucci J; Malouf D; Gillatt D; Li Y
Oncotarget; 2016 Nov; 7(45):74269-74285. PubMed ID: 27708237
[TBL] [Abstract][Full Text] [Related]
12. PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.
Wu DD; Gao YR; Li T; Wang DY; Lu D; Liu SY; Hong Y; Ning HB; Liu JP; Shang J; Shi JF; Wei JS; Ji XY
BMC Cancer; 2018 May; 18(1):499. PubMed ID: 29716528
[TBL] [Abstract][Full Text] [Related]
13. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
[TBL] [Abstract][Full Text] [Related]
14. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
15. Deglycosylation of epithelial cell adhesion molecule affects epithelial to mesenchymal transition in breast cancer cells.
Liu X; Yang L; Zhang D; Liu T; Yan Q; Yang X
J Cell Physiol; 2019 Apr; 234(4):4504-4514. PubMed ID: 30246502
[TBL] [Abstract][Full Text] [Related]
16. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
17. Ursolic Acid Induces Apoptosis of Prostate Cancer Cells via the PI3K/Akt/mTOR Pathway.
Meng Y; Lin ZM; Ge N; Zhang DL; Huang J; Kong F
Am J Chin Med; 2015; 43(7):1471-86. PubMed ID: 26503559
[TBL] [Abstract][Full Text] [Related]
18. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
[TBL] [Abstract][Full Text] [Related]
19. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
[TBL] [Abstract][Full Text] [Related]
20. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
